MEMPHIS, Tenn.--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) announced today that the U.S. Food and Drug Administration has granted an investigational device exemption (IDE) to the DIAM™ Spinal Stabilization System for use in a second U.S. clinical study. This prospective, randomized, controlled pivotal IDE clinical trial will attempt to prove the DIAM Spinal Stabilization System is superior to conservative care for patients with low back pain caused by degenerative disc disease (DDD).
